+#.# Yuan

Related by string. * + #.#s [002] . + #.#s [003] . +#.# [006] . +#.# [008] . +#.# [007] . +#.# [001] . +#.# [005] . +#.# [002] : +#.# % =mitochondrial pathway . +#.# bn compared . +#.# +#.# % [002] . Trades +#.# % . +#.# % [002] . DJIA +#.# % . #.#/bbl +#.# % / yuans . YUAN . Yuans . yuan : bln yuan . yuan peg . trillion yuan . Examination Yuan . Legislative Yuan . yuan artificially . yuan revaluation * *

Related by context. All words. (Click for frequent words.) 71 -#.# USD JPY [002] 60 Gainsco -#.# % 57 Axa SA -#.# 56 Home Properties HME 54 -#.# p = 54 ß = 54 Unitrin +#.# 53 Chris Rivas Buell 53 #.# US#YT = 53 CI -#.# 53 Amer Cent 52 #.#-#.# p = 52 Cruz Pedregon Monte Carlo 52 AUTOMATIC WITH OVERDRIVE 52 Companhia Siderugica Hacional 51 Pricesmart NASDAQ PSMT 51 BMS p = 51 -#.# mmol L 51 Class Pr TSX 50 Etf Un TSX 50 -#.# log# 50 Cl b Nv 50 Ultra Financials ProShares 50 Pac Lf 49 Efficiency ratio FTE 49 THOMPSON CREEK METALS 49 Corp. Pr TSX 49 Cl TSX 49 ORD 5P 49 CELESTICA 49 Adjusted Margin 49 Xalatan R 49 CAPITAL ACCOUNT 49 Recap BAL 49 % Confidence Interval 48 call QNQ 48 neuropathy sensory 48 Pr TSX 48 RICE BRAN Rs 48 48 Parkin DM 48 placebo Hazard Ratio 48 Brief Psychiatric 47 MC# [001] 47 Fnd 47 spud #-#-# drlg [004] 47 CoreLogic CLGX 47 Efficiency ratio taxable 47 Biodel NASDAQ BIOD 47 MAINTAINS BUY 47 BlackRock MuniVest Fund 47 LONG BEACH Mffais.com Voyageur 47 OZG 47 mmHg p = 47 Columbia Glbl Value 47 P ≤ 46 Luminex Corporation LMNX 46 Claymore Tax Advantaged 46 r2 = 46 -#.# ± [002] 46 ALT elevation 46 FRANK JOHNSON 46 BlackRock MuniHoldings Insured 46 mg p = 46 Fin Serv 45 mU liter 45 prednisone prednisolone plus 45 ppm deg 45 Interest Coverage Ratio 45 Universal UVV 45 HOMA IR 45 % CI #.#-#.# [001] 45 Yield Bond 45 Newsflashes 45 spud #-#-# drlg [002] 45 Dillards DDS 45 adefovir treated 45 Tredegar Corporation 45 confidence interval #.#-#.# 45 JOE 'S RESTAURANT 44 CI #.#-#.# [002] 44 CUSIP #G# 44 placebo p = 44 Rating Scale BPRS 44 p = .# [002] 44 statistical significance p 44 CI -#.# -#.# 44 echocardiographic parameters 44 TIM McMANUS 44 Pr Ser TSX 44 mean baseline A1C 44 kappa = 44 rho = 44 CI #.#-#.# p = 44 baseline FEV 44 beta coefficient 44 bivalirudin monotherapy 43 Morgan Stanley Emerging Markets 43 = #.#-#.# 43 Stent p = 43 Affiliated Insurers 43 x ULN 43 TIMP 1 43 Cystatin C 43 SPECIFICS Hosston 43 stimulated insulin secretion 43 PEY 43 mg BID dose 43 call KCQ 43 statistically significant p = 43 -#.# mm Hg 43 confidence interval CI 43 Swedish Krona Trust 43 HBeAg negative patients 43 ^ sup + 43 #a #a [003] 43 Energy ETF VDE 43 multivariate adjusted 43 CurrencyShares Swedish Krona 42 PYN 42 β = 42 ischemia driven 42 CIBC CM 42 ATV RTV 42 Parallax Fund 42 Live Equiv 42 MSCI NYSE MXB 42 placebo p 42 CIBIC plus 42 CC genotype 42 esophagus bladder 42 PKY 42 -#.# ± [001] 42 = .# 42 Secondary endpoints included 42 Tables Attached 42 PIA XI top 42 multivariable adjusted 42 mean ± SEM 42 Partial Response 42 cyclophosphamide methotrexate 42 % CI #.#-#.# [005] 42 Southeast Anesthesiology Consultants 42 multivariate Cox 42 logistic regression analysis 42 UVV 42 UltraPro Short S 42 ezetimibe simvastatin 42 interrater reliability 42 Marketocracy Capital 42 Faircourt Asset Management 41 EOX 41 Collectors Universe NASDAQ CLCT 41 Trust Transferable Units 41 Precision Drilling PDS 41 RSY 41 Papillary 41 visit www.conservation.org 41 estimated GFR 41 TGZ 41 call ORQ 41 lumbar spine BMD 41 By JIM TATUM 41 pmol L 41 HZW 41 SCZ 41 Gazeta Wyborcza pp. 41 catechol O methyltransferase 41 specific alkaline phosphatase 41 # #-# [006] 41 albumin excretion rate 41 #.#/#.# mmHg [001] 41 LP# [001] 41 MADRS score 41 % CI #.#-#.# [004] 41 Hazard Ratio = 41 By MARTIN CAHN 41 statistically significant p 41 pT 41 PCWP 41 LV ejection fraction 40 call RFY 40 invasive carcinomas 40 PHAROS 40 ug dose 40 Tenaris NYSE 40 BVN 40 Metavante Technologies Inc 40 Prostate specific antigen 40 r = 40 Cognitively Impaired 40 Puls Biznesu pp. 40 CGIC 40 WR Berkley NYSE WRB 40 hyperhomocysteinemia 40 PFCO 40 % CI #.#-#.# [003] 40 mL/min/#.# m 2 40 Relapsing remitting 40 fludarabine cyclophosphamide 40 INCOME TRUST 40 antibiotics metronidazole 40 DAS# CRP 40 HBeAg seroconversion 40 p = NS 40 Median PFS 40 Faircourt Split Trust 40 Normalized EPS 40 CI #.#-#.# [001] 40 CI = 40 TECK 40 Friends Provident LSE 40 preoperative PSA 40 pulsatility index 40 oxycodone CR 39 CFQ R 39 collagenous colitis 39 FirstRand firmed 39 % CI #.#-#.# [006] 39 Skylon Capital 39 Pearson correlation coefficient 39 Main Outcome Measures 39 #a #a [001] 39 bioavailable testosterone 39 Operative mortality 39 TRIST 39 rs# [004] 39 Chronic Obstructive Lung 39 β blocker 39 p = .# [001] 39 lowest tertile 39 heterozygotes 39 surgically resected 39 regression coefficient 39 IRLS 39 TIMP 39 SF #v# 39 CABG p = 39 completely resected 39 Comorbidity 39 % CI #.#-#.# [007] 39 Postmenopausal hormone therapy 39 Neenah Paper NYSE 39 PSQI 39 clodronate 39 BNX 39 Cronbach alpha 39 advanced hepatocellular carcinoma 39 Industrier 39 Consolidated Edison Inc 39 plasma adiponectin 39 pT3 39 RIGScan R 39 drotrecogin alfa activated 39 HBeAg 38 elevated transaminases 38 CLY 38 SDY 38 creatinine ratio 38 xenograft model 38 MBq 38 Compl. ¶ ¶ 38 IXJ 38 QTcF 38 Angiotensin converting enzyme 38 Document Maker 38 ValueAct Capital Master 38 MXB 38 odds ratios ORs 38 pretest probability 38 CRu 38 confidence intervals CIs 38 NYSE CSFS 38 achieved ACR# 38 glucocorticoid induced 38 aOR 38 tPSA 38 microg 38 TURBT 38 HRCT 38 Global Impression CGI 38 subjective sleepiness 38 atorvastatin #mg 38 mmHg diastolic 38 Main Outcome Measure 38 μg mL 38 Kaplan Meier analysis 38 multivariable Cox 38 μmol L 38 Mid Cap Core 38 biochemical relapse 38 SSc 38 dose atorvastatin 38 Aweida Capital 38 p ≤ 38 CR CRu 38 ANCOVA 38 NMIBC 38 mmol L 38 nonobstructive 37 % CI #.#-#.# [008] 37 % CI #.#-#.# [002] 37 statistically significant predictor 37 pg mL 37 de novo coronary artery 37 mIU ml 37 df = 37 prespecified secondary 37 intraclass correlation coefficients 37 laparoscopic radical nephrectomy 37 NFV 37 Transglobe Energy 37 pg ml 37 serologically active patients 37 correlation coefficient 37 CR nPR 37 adriamycin 37 LMP Real Estate 37 SGRQ 37 Ischemic heart 37 mol L 37 pulmonary exacerbations 37 sd = 37 #OHD 37 nonsignificant difference 37 metronidazole gel 37 mITT population 37 urine albumin 37 LDL triglycerides 37 inflammatory rheumatic 37 Brompton Advantaged Tracker 37 seropositivity 37 ALTE 37 radiotherapy RT 37 carotid IMT 37 correlation coefficients 37 PaO 2 37 intraclass correlation coefficient 37 IPSS 37 hc2 37 Cardiopulmonary bypass 37 Disease Activity 37 BlackRock Floating Rate 37 pCR 37 Panoro Minerals 36 NNT = 36 SELENA SLEDAI 36 bronchioloalveolar carcinoma 36 Int'l Paper 36 HF hospitalization 36 preintervention 36 recurrent DVT 36 ARCOXIA 36 P = .# 36 variant rs# 36 obstructive CAD 36 Severity CGI S 36 microbiologically evaluable 36 pN 36 Index FSFI 36 pretreatment serum 36 multiple logistic regression 36 Canara Robeco Balance 36 function subscale 36 Abnormal Involuntary Movement 36 Assurance SCA 36 Hazard Ratio 36 Platelet counts 36 serum concentrations 36 AIQ 36 p = 36 TRUS 36 CALGB # [002] 36 BTZ 36 â ‰ ¥ 36 nondiabetic patients 36 Seattle Angina Questionnaire 36 p = ns 36 Small Cap Core 36 interquartile range 36 clinically meaningful improvement 36 Avg Yield 36 hormone receptor negative 36 ECOG PS 36 TPV r 36 mL/min/#.# m2 36 CRp 36 invasive lobular 36 Kaplan Meier estimates 36 mU L 36 nonfatal MI 35 Charlson comorbidity index 35 WOMAC pain 35 NIH CPSI 35 interrater 35 chromosome #q#.# [002] 35 gm dl 35 Artisan Mid Cap 35 Intermediate Muni 35 Secondary endpoints include 35 FGFR4 35 mesangial 35 sodium nitroprusside 35 MMSE score 35 ERBB2 35 ABIH 35 seronegative 35 pain subscale 35 SNP rs# [002] 35 Hb A1C 35 pT2 35 fluoropyrimidine 35 QVAR R 35 tHcy 35 lymphocytosis 35 atherosclerotic renal artery stenosis 35 total cholesterol HDL 35 IFN alfa 35 multivariable analysis 35 thyroid carcinoma 35 complete cytogenetic response 35 CORE OM 35 HFRX 35 familial aggregation 35 renal allograft 35 mmol L. 35 #p# [003] 35 Credicorp Ltd. BAP 35 Supplemental Figure 35 Assessment Scale 35 Vanguard Small Cap 35 EGFR mutation positive 35 Oncotype 35 aortic calcification 35 EQ 5D 35 UPDRS motor 35 Applied Biodiversity 35 ratio ICER 35 subscores 35 nadroparin 35 #.#-#.# [005] 35 clinicopathological 35 1st Pr TSX 35 p = #.# [003] 35 μg ml 35 CI# [002] 35 bivariate 35 NRTI sparing 35 IPAH 35 Skin sterol 35 atherothrombotic 35 CIN2 + 35 CNH Equipment 35 BEXXAR Therapeutic Regimen 35 p = #.# [002] 35 DAS# [002] 35 lymph node metastasis 35 undergo percutaneous coronary 35 tipranavir ritonavir 35 undetectable HBV DNA 35 intraabdominal 35 biopsy Gleason 35 Credicorp Ltd 34 IOP lowering 34 Ansvar 34 leukemia lymphomas 34 BULLETIN TYPE Graduation 34 FOLFIRI alone 34 Seylan Merchant Bank 34 Rydex Inverse 2x 34 Neurobiological 34 ß blockers 34 diameter stenosis 34 mL kg 34 Vascular Stent 34 mHRPC 34 KRAS gene mutations 34 GG genotype 34 KDOQI 34 Preoperatively 34 BFSL 34 LV dysfunction 34 enterococcal 34 Calamos Convertible Opportunities 34 conjugated equine estrogens 34 Troj Bancban 34 advanced adenomas 34 neurologic impairment 34 antiretroviral naïve 34 mucosal inflammation 34 About ChoicePoint ChoicePoint 34 intima media thickness 34 plus medroxyprogesterone acetate 34 Wechsler Adult 34 www.ci.com cix 34 IQR 34 PLND 34 highest quintile 34 metabolomic profiles 34 EORTC QLQ C# 34 Company OSE PGS 34 binary restenosis 34 p = #.# [004] 34 CI 34 RECIST criteria 34 lymphocyte count 34 FluCAM arm 34 coronary stenosis 34 advanced pancreatic neuroendocrine 34 adjuvant radiotherapy 34 angiographically 34 noninferiority 34 mIU L 34 systemic embolism 34 gastroduodenal 34 International Prognostic Scoring 34 COMT genotype 34 AJG 34 nmol 34 Nuveen Premium 34 primary ciliary dyskinesia 34 Sharpe Ratio 34 HCV antibody 34 TTM EPS 34 ± 33 highest tertile 33 NNRTI resistance 33 ROC curve 33 nonfatal myocardial infarction 33 pretransplant 33 Geologic Resource 33 Cigna Corp 33 Arbor Networks Peakflow 33 Kaplan Meier method 33 PDSS 33 BPS IC 33 periprocedural 33 HLA DRB1 SE 33 recurrent venous thromboembolism 33 urinary excretion 33 node metastases 33 BPRS 33 colorectal adenoma 33 PSA nadir 33 RECIST 33 subscale scores 33 DRN 33 salmeterol fluticasone propionate 33 symptomatic intracranial hemorrhage 33 T1a 33 hypertension hypercholesterolemia 33 T1c 33 multivariate adjustment 33 AUCs 33 CRQ 33 NYHA functional class 33 HRQL 33 Flagstone Reinsurance 33 VFQ 33 extracapsular extension 33 p 33 EuroSCORE 33 subscore 33 nonfatal stroke 33 autologous SCT 33 cilostazol 33 multivariable logistic regression 33 thromboemboli 33 cytogenetic abnormalities 33 Metabase 33 LCX 33 lymphovascular invasion 33 fatal myocardial infarction 33 clinically evaluable CE 33 underwent resection 33 advanced adenoma 33 progression TTP 33 SUVmax 32 QRS duration 32 Viread Emtriva SUSTIVA 32 prostatic adenocarcinoma 32 SecureInfo RMS 32 treat NNT 32 HLA A2 32 #p#.# [001] 32 sleeve lobectomy 32 PSADT 32 Pneumocystis carinii pneumonia 32 serum biomarker 32 CTEPH 32 histologically proven 32 hemoglobin hematocrit 32 sensory neuropathy 32 squamous intraepithelial lesions 32 Investable Index 32 parous women 32 serum alkaline phosphatase 32 thromboembolism 32 secondary efficacy endpoint 32 Adjuvant chemotherapy 32 symptomatic intracerebral hemorrhage 32 cytoreductive nephrectomy 32 noncardiovascular mortality 32 CAPVEST Income Corp. 32 OR 32 Logistic regression 32 ECG abnormalities 32 CKK 32 eplerenone 32 RNA copies mL 32 atrial natriuretic peptide 32 statistical significance p = 32 iodixanol 32 thrombocytopenic 32 NRR 32 HFN database 32 LVEF 32 mesilate 32 cm H2O 32 bivalirudin alone 32 prevalences 32 reinfarction 32 multivariate analyzes 32 inhospital mortality 32 anagrelide 32 T1 hypointense lesions 32 Supplementary Table 32 CYPHER ® 32 MetS 32 convergence insufficiency 32 symptomatic DVT 32 Score DAS# 32 parasitological 32 oblimersen 32 ertapenem 32 hydronephrosis 32 Alleanza Assicurazioni 32 TT genotype 32 Multivariate analysis 32 β blockers 31 spontaneous bacterial peritonitis 31 independent prognostic marker 31 Net Tangible Assets 31 myocardial infarction stroke 31 SBP DBP 31 BALF 31 mutated p# 31 HbA 1c levels 31 median PFS 31 Median progression 31 nonischemic 31 undergoing radical cystectomy 31 anthracycline containing 31 RY 31 Corp. TSX CIX 31 pegylated interferon alfa 2b 31 ECLS 31 mRS 31 postintervention 31 intraperitoneally 31 PEEP 31 ximelagatran 31 Megace ® 31 RNFL thickness 31 Rockwater Capital 31 FLD 31 tamoxifen Nolvadex ® 31 recessively inherited 31 diastolic velocity 31 nonexposed 31 Karim Helal managing 31 FLOMAX 31 Research Diagnostic Criteria 31 simvastatin #mg 31 serum GGT 31 CIBIC + 31 undergoing coronary angiography 31 IIIb 31 arterial thromboembolic events 31 YLO.UN 31 ‰ ¥ 31 CBV 31 del 5q 31 carboxy 31 AGIC 30 Secondary efficacy endpoints 30 preoperative chemotherapy 30 PHILADELPHIA Hersha Hospitality 30 polyp recurrence 30 familial AF 30 Confidence Intervals 30 BSIs 30 prostate cancer CaP 30 interval #.#-#.# 30 SSP CID 30 conditional logistic regression 30 Linear regression 30 Evaluable 30 Corp Banca 30 5q 30 sociodemographic factors 30 subclinical atherosclerosis 30 HSCR 30 Oncotype DX Recurrence Score 30 Sirona Holdings Luxco 30 SCA SCA 30 artery occlusion 30 5-FU/LV 30 hematologic toxicity 30 peri procedural 30 FID Funds 30 FBP 30 KeySpan Facilities 30 WAT 30 AOR = 30 β thalassemia 30 plasmacytoid 30 seminal vesicle invasion 30 Kruskal Wallis test 30 HIV uninfected 30 CsA 30 Acuity Funds 30 Stage IIIb 30 stage IIIA 30 atrophic gastritis 30 standard deviation 30 recurrent ischemic 30 IIEF 30 subscales 30 lacunar 30 biochemical recurrence 30 ¶ ¶ #-# 30 HGPIN 29 univariate analysis 29 detrusor overactivity 29 oncological outcomes 29 QALYs 29 univariate analyzes 29 malignant phenotype 29 sustained ventricular tachycardia 29 Fig. 3b 29 sero positive 29 response pCR 29 ENGAGE AF TIMI 29 vasopressor 29 histologically confirmed 29 nonsignificant 29 Injury Severity Score 29 IFN beta 1a 29 MI 29 posttreatment 29 Cushing MLP 29 cytologic 29 mg clopidogrel 29 Symptom Checklist 29 Birla Dividend Yield 29 Multivariate analysis revealed 29 carotid artery thickness 29 lymphadenectomy 29 Fanuc #i 29 FDG PET scan 29 SVF 29 JUM 29 PCa 29 debulking surgery 29 achieve sustained virological 29 haematological toxicity 29 IIQ 29 receiving VICTRELIS 29 HGD 29 ventilation perfusion 29 oral diclofenac 29 TriZetto Advantage 28 Cash Drawer 28 normotensive 28 covariate 28 catheter colonization 28 HBV infected 28 androgen suppression 28 acute cholecystitis 28 Bovi Shield GOLD 28 carotid artery ICA 28 postop 28 radical prostatectomy RP 28 recurrent VTE 28 mean baseline HbA1c 28 Abstract P# [002] 28 ACAT 28 CML Healthcare 28 Enerflex Systems 28 UPDRS scores 28 WHH 28 28 euthyroid 28 Kaplan Meier 28 comorbid 28 Multimanager 28 advanced neoplasia 28 NP 28 HSMI 28 SciVest 28 CLF 28 gene APOE 27 SDQ 27 +5' 27 AHR 27 idraparinux 27 noncardiac 27 CIBIC Plus 27 GWO 27 distant metastasis 27 CPFIS 27 ProVen 27 lowest quintile 27 NetSupport DNA 27 retrospective cohort 27 amoxicillin clavulanate 27 MAP 27 MIs 27 atazanavir ritonavir 27 nodal metastasis 27 FI 27 OVX 27 Talsyn 27 tertiles 27 RBC transfusion 27 Dexx & 27 proportional hazards 27 IFIS 27 South Grand Lahou 27 Cardiogenic shock 27 MGUS 27 Short Duration Bond 27 iUnits 27 LV systolic function 27 NEPT 27 OM 27 CHD 27 FER 27 Losartan Intervention 26 Merger arbitrage 26 nonvertebral fracture 26 HRQoL 26 logistic regression model 26 RR 26 borderline statistical significance 26 BPV 26 untreated CLL 26 adverse cytogenetics 26 malignant neoplasm 26 latent celiac disease 26 PSQ 26 liver transplant recipients 26 Fenchurch Advisory Partners 26 ICAM 26 apoE4 carriers 26 CAPIC 26 IMA Absolute Return 26 ipsilateral stroke 26 FPH 26 CI Mutual Funds 26 CPX 26 CF Miton 26 Howson Tattersall 26 CMI 26 JK Ansell 26 LGG 25 Segregated Funds 25 GBD 25 diversiTrust TM Energy 25 Russell A. Mittermeier 25 BREF 25 CHH 25 antithrombotic therapy 25 SPARCS 25 Gustavo Fonseca 25 TS 25 IPTp 25 observational cohort 25 portal vein thrombosis 25 Schwab Yield 25 SunGard APT 25 OASI 25 Severe Acute Malnutrition 25 Niemann Pick type 25 PSGs 25 HIAA 25 Alia Mamdouh 25 PRM 25 n = 25 24 CanLII 24 multivariate analysis 24 Hg 24 sq cm 24 RSG 24 Nrg 24 aged ≥ 24 Dundee Wealth Management 24 coincident composite index 24 anastomotic leaks 24 exemestane 24 AllBlue 24 DBMD 24 VT VF 24 PABC 24 Brompton VIP 24 CIs 24 NYLIM 24 PH 23 GCAN 23 PCSM 23 SFM 23 UTI Retirement 23 GHI 23 CIGNA NYSE 23 colorectal neoplasms 23 SIAT 23 HPFS 23 GPI 23 CMR 23 OPRM1 23 CQR 23 PI 23 Steelmaker Ipsco Inc. 22 myocardial infarction 22 Francois Barthelemy 22 BCP 22 Amodiaquine 22 SCIP 22 KLSE Composite Index 21 PME 21 Nova Scotia BNS 21 PCSS 21 SBM 21 Mackenzie Cundill Value 21 MLI 21 Confidential Informant 21 BlackRock MLIM 21 ICICI Pru 21 TSX CIX.UN 21 Trimark Fund 21 Conditional Access Module 21 DIAN 21 MACE 20 TNM 20 DR 20 Billets 20 EHP 20 LOF 20 SCS 20 Evton Real Estate 20 endovascular graft 20 TSX CIX 20 Markham Stouffville 20 Mackenzie Cundill 19 GHL 19 FLT 19 Jeevan Akshay 19 Dundee Wealth 19 Assante Asset Management 19 Rockwater Capital Corp. 18 FIO 18 LIF 18 RMS 18 point Likert scale 18 SCA 17 VNB 17 Clarica 17 ACR 17 IGM 17 MPM 17 Medisys 17 LOQ 16 Pension Adjustment 16 BPS 15 Guaranteed Maturity 15 RAP 15 GARS 15 Assante Wealth Management 15 MMF 15 BCSS 15 AGF 14 Clearwater Seafoods Income 14 SunWise Elite Plus 14 CIC 14 CFS 14 APF 13 GraceKennedy 12 ICD 12 RBTT 12 DundeeWealth 12 MDS 12 HPS 11 CTFS 10 Clico 9 Manulife 9 AIC 8 Scotia

Back to home page